EVOTEC SE (1EVT.MI) Stock Price & Overview
BIT:1EVT • DE0005664809
Current stock price
The current stock price of 1EVT.MI is 4.494 EUR. Today 1EVT.MI is up by 6.34%.
1EVT.MI Key Statistics
- Market Cap
- 799.393M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.11
- Dividend Yield
- N/A
1EVT.MI Stock Performance
1EVT.MI Stock Chart
1EVT.MI Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to 1EVT.MI.
1EVT.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to 1EVT.MI. 1EVT.MI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
1EVT.MI Earnings
On November 5, 2025 1EVT.MI reported an EPS of -0.12 and a revenue of 163.89M. The company missed EPS expectations (-3.31% surprise) and missed revenue expectations (-9.17% surprise).
1EVT.MI Forecast & Estimates
13 analysts have analysed 1EVT.MI and the average price target is 7.33 EUR. This implies a price increase of 63.08% is expected in the next year compared to the current price of 4.494.
For the next year, analysts expect an EPS growth of 61.33% and a revenue growth -1.62% for 1EVT.MI
1EVT.MI Groups
Sector & Classification
1EVT.MI Financial Highlights
Over the last trailing twelve months 1EVT.MI reported a non-GAAP Earnings per Share(EPS) of -1.11. The EPS decreased by -136.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -8.97% | ||
| ROE | -19.87% | ||
| Debt/Equity | 0.48 |
1EVT.MI Ownership
1EVT.MI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| DIM | SARTORIUS STEDIM BIOTECH | 35.11 | 16.926B | ||
| 56S1 | SARTORIUS STEDIM BIOTECH | 33.09 | 16.585B | ||
| SRT3 | SARTORIUS AG-VORZUG | 40.06 | 16.219B | ||
| SRT | SARTORIUS AG | 31.58 | 12.834B | ||
| QIA | QIAGEN N.V. | 16.12 | 7.285B | ||
| 1SXP | SCHOTT PHARMA AG& CO KGAA | 13.2 | 2.096B | ||
| EVT | EVOTEC SE | N/A | 836.036M | ||
| GXI | GERRESHEIMER AG | 6.88 | 589.943M | ||
| FF | FINE FOODS & PHARMACEUTICALS | 14.57 | 189.275M | ||
| ALECR | EUROFINS CEREP-REGR | N/A | 158M | ||
| MLC | MALIN CORP PLC | N/A |
Related stock screener links
View all stocks in the Life Sciences Tools & Services Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Milan Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About 1EVT.MI
Company Profile
Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. The company is headquartered in Hamburg, Hamburg and currently employs 4,788 full-time employees. The firm is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Company Info
IPO: 1999-10-11
EVOTEC SE
Essener Bogen 7
Hamburg HAMBURG DE
Employees: 4788
Phone: 4940560810
EVOTEC SE / 1EVT.MI FAQ
Can you describe the business of EVOTEC SE?
Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. The company is headquartered in Hamburg, Hamburg and currently employs 4,788 full-time employees. The firm is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
What is the current price of 1EVT stock?
The current stock price of 1EVT.MI is 4.494 EUR. The price increased by 6.34% in the last trading session.
Does EVOTEC SE pay dividends?
1EVT.MI does not pay a dividend.
What is the ChartMill technical and fundamental rating of 1EVT stock?
1EVT.MI has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the market expecting 1EVT stock to perform?
13 analysts have analysed 1EVT.MI and the average price target is 7.33 EUR. This implies a price increase of 63.08% is expected in the next year compared to the current price of 4.494.
How is the valuation of EVOTEC SE (1EVT.MI) based on its PE ratio?
EVOTEC SE (1EVT.MI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.11).